EUVIMEDEUVIMED entdecken
Systematische Übersicht

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials

Jia Liu iD, Max Farrow, Lesley Seymour iD, Jayesh Desai iD, Herbert H Loong iD, Percy Ivy iD, Takafumi Koyoma iD, Natalie Cook, Sarah Blagden iD, Elena Garralda iD, Christophe Massard iD, Anthony W Tolcher und 8 weitere

Journal of Clinical Oncology · 2025

DOI: 10.1200/jco-24-01534 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Clinical Oncology, 2025. Verfasst von Jia Liu und 19 weiteren Autor:innen. Beteiligte Einrichtung: The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Drug Development, Precision Medicine, Neoplasms, Medical Oncology. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 90 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Over the past 15 years, the landscape of early phase clinical trials (EPCTs) has undergone a remarkable expansion in both quantity and intricacy. The proliferation of sites, trials, sponsors, and contract research organizations has surged exponentially, marking a significant shift in research conduct. However, EPCT operations suffer from numerous inefficiencies, such as cumbersome start-up processes, which are particularly critical when drug safety and the recommended phase II dose need to be established in a timely manner. Networks and consortia may overcome some of these challenges of enrolling suitable patients and streamlining start-up, particularly when distance and disease trajectory come into play. DESIGN In this article, we provide an overview of EPCT consortia in adult oncology across different continents assembled through systematic review of the literature and snowball sampling methodology. We illustrate their scope, structure, funding, and achievements. RESULTS Fifteen EPCT consortia were identified including two in the United States, three in Europe, five in Asia-Pacific, two intercontinental consortia, and three within private oncology networks. These consortia vary in their scope, funding, and structure from government-funded models such as the National Cancer Institute Experimental Therapeutics Clinical Trials Networks through charitably funded and private research organizations. EPCT consortia play a role in collaborative research, molecular tumor boards to provide patient-centric biomarker-matched treatments, and streamlining trial conduct to improve timelines and cost efficiency. CONCLUSION The growth in EPCT activity and complexity has resulted in expansion in the number of EPCT consortia globally. By actively engaging with regulatory bodies and pharmaceutical and contract research organization industries, consortia have an opportunity to address the evolving challenges faced in this field and to accelerate the translation of scientific discoveries into clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentPrecision MedicineNeoplasmsMedical OncologyClinical Trials as TopicAntineoplastic AgentsHumans

Substanzen

Antineoplastic Agents

Autor:innen und Institutionen

  • The Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia.
  • Faculty of Medicine & Health, School of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia.
  • Garvan Institute of Medical Research, Sydney, NSW, Australia.
  • Canadian Cancer Trials Group, Queens University, Kingston, ON, Canada.
  • Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR, China.

ORCID-Profile: Jia Liu, Lesley Seymour, Jayesh Desai, Herbert H Loong, Percy Ivy, Takafumi Koyoma, Sarah Blagden, Elena Garralda, Christophe Massard, Jacob J Adashek, Li Zhang, Lin Shen, Razelle Kurzrock, Vivek Subbiah, Anthony M Joshua

Zitieren

APA

Liu, J., Farrow, M., Seymour, L., Desai, J., Loong, H. H., Ivy, P., Koyoma, T., Cook, N., Blagden, S., Garralda, E., Massard, C., Tolcher, A. W., Adashek, J. J., Zhang, L., Zhao, S., Shen, L., Kurzrock, R., El-Deiry, W. S., Subbiah, V., & Joshua, A. M. (2025). Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials. Journal of Clinical Oncology. https://doi.org/10.1200/jco-24-01534

Vancouver

Liu J, Farrow M, Seymour L, Desai J, Loong HH, Ivy P, et al. Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials. Journal of Clinical Oncology. 2025. doi:10.1200/jco-24-01534

BibTeX
@article{Liu2025,
  author = {Liu, Jia and Farrow, Max and Seymour, Lesley and Desai, Jayesh and Loong, Herbert H and Ivy, Percy and Koyoma, Takafumi and Cook, Natalie and Blagden, Sarah and Garralda, Elena and Massard, Christophe and Tolcher, Anthony W and Adashek, Jacob J and Zhang, Li and Zhao, Shen and Shen, Lin and Kurzrock, Razelle and El-Deiry, Wafik S and Subbiah, Vivek and Joshua, Anthony M},
  title = {Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1200/jco-24-01534}
}
Kostenlos starten →